AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Genmark11/17/2023 ![]() “The rapid identification of bloodstream infections and the detection of antimicrobial resistance genes are more essential than ever for hospitals and their patients. “Their proven expertise in syndromic panel testing provides faster targeted therapeutic intervention, resulting in improved patient outcomes and reduced hospital stays, and will contribute to Roche’s commitment to helping control infectious diseases and antibiotic resistance. Jordan Genmark Heath (15) Linebacker - UCLA Enrolled at UCLA in January of 2021 after graduating from Notre Dame and participated in 2021 spring ball. As one of the most recent additions to the syndromic testing landscape, the ePlex platform by GenMark Diagnostics is a system that combines the manufacturer's signature electrochemical detection technology with updated microfluidics, providing a new option for multiplex testing that is both rapid and requires minimal hands-on steps. The Company offers system that supports a broad. Genmark’s MiniMax Equipment Front End Module (EFEM) is a class 1 minienvironment system designed to maximize productivity of semiconductor processing equipment tools that require the highest level of automation. ![]() Roche Diagnostics CEO Thomas Schinecker said: “Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases. operates as a molecular diagnostics company focused on developing and commercializing its biomarker detection technology. ![]() ![]() GenMark’s Respiratory Pathogen Panels can detect the most common viral and bacterial organisms associated with an upper respiratory infection, including SARS-CoV-2, complementing Roche’s Covid-19 diagnostics solutions portfolio. GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. The addition of the company’s syndromic panel testing portfolio expands Roche’s molecular diagnostics portfolio. ![]()
0 Comments
Read More
Leave a Reply. |